Form 4: KalVista CDO Sells Shares for Tax Obligations
Insider Transaction Report
KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, reported the sale of 2,683 common shares to cover tax withholding obligations related to restricted stock unit vesting.
Summary
- Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, Inc., reported transactions involving the company's common stock.
- On November 17, 2025, Yea acquired 4,205 shares of common stock through the settlement of Restricted Stock Units (RSUs).
- On November 18, 2025, Yea sold 2,683 shares of common stock at a weighted average price of $14.4794 per share.
- This sale was explicitly stated as a "sell to cover" transaction to satisfy tax withholding obligations arising from the RSU vesting and was not a discretionary sale.
- Following these transactions, Yea beneficially owns 133,574 shares of KalVista Pharmaceuticals, Inc. common stock.
Sentiment
Score: 5
Explanation: The filing reports a routine 'sell to cover' transaction by an insider to satisfy tax obligations related to RSU vesting. This is a non-discretionary event and typically has a neutral sentiment impact on the company's stock.
Future Outlook
NA
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction, specifically a 'sell to cover' related to RSU vesting. It does not provide broader industry context or competitive analysis, as its purpose is to report changes in beneficial ownership by an insider.
Stakeholder Impact
- Shareholders: Minimal direct impact as the transaction is a routine, non-discretionary sale for tax purposes, not indicative of a change in management's confidence or a significant shift in ownership structure.
Key Dates
| Date | Description |
|---|---|
| 11/17/2025 | Date of acquisition of 4,205 common shares through RSU settlement. |
| 11/18/2025 | Date of sale of 2,683 common shares to cover tax withholding obligations. |
| 11/19/2025 | Date the Form 4 was signed by Attorney-in-Fact. |
Recommendation
holdThe filing details a routine 'sell to cover' transaction by a Chief Development Officer to satisfy tax obligations upon RSU vesting. This is a non-discretionary event and does not reflect a change in the insider's view of the company's prospects. Therefore, it provides no new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.
Keywords
KalVista Pharmaceuticals, KALV, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Sale, Tax Withholding, Christopher Yea, Chief Development Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.